Leerink Partnrs Analysts Cut Earnings Estimates for MLTX

Key Points

• Leerink Partners has revised its Q3 2025 earnings per share (EPS) estimate for MoonLake Immunotherapeutics to ($0.96), down from a previous estimate of ($0.80).
• The consensus estimate for the company's full-year earnings in 2025 stands at ($1.79) EPS, with projections predicting further losses through 2027 before potentially returning to profit in 2028.
• Despite the negative earnings outlook, MoonLake Immunotherapeutics has an average rating of "Moderate Buy" from analysts and an average price target of $74.43.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Equities research analysts at Leerink Partnrs decreased their Q3 2025 EPS estimates for MoonLake Immunotherapeutics in a research note issued on Tuesday, August 5th. Leerink Partnrs analyst T. Smith now anticipates that the company will post earnings of ($0.96) per share for the quarter, down from their previous forecast of ($0.80). The consensus estimate for MoonLake Immunotherapeutics' current full-year earnings is ($1.79) per share. Leerink Partnrs also issued estimates for MoonLake Immunotherapeutics' Q4 2025 earnings at ($0.98) EPS, FY2025 earnings at ($3.45) EPS, FY2026 earnings at ($4.58) EPS, FY2027 earnings at ($5.29) EPS, FY2028 earnings at $1.45 EPS and FY2029 earnings at $7.85 EPS.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.14). During the same period in the previous year, the firm earned ($0.39) EPS.

Several other research firms also recently commented on MLTX. Rothschild & Co Redburn initiated coverage on shares of MoonLake Immunotherapeutics in a report on Monday, July 28th. They issued a "neutral" rating and a $65.00 target price on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $66.00 price target on shares of MoonLake Immunotherapeutics in a research note on Tuesday, May 13th. Redburn Atlantic raised shares of MoonLake Immunotherapeutics to a "hold" rating in a research note on Monday, July 28th. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $67.00 price target on shares of MoonLake Immunotherapeutics in a research note on Tuesday, June 3rd. Finally, Wedbush reaffirmed an "outperform" rating and set a $80.00 price target (up previously from $78.00) on shares of MoonLake Immunotherapeutics in a research note on Tuesday, May 13th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $74.43.

MoonLake Immunotherapeutics Price Performance

Shares of MLTX stock traded up $0.51 during mid-day trading on Friday, hitting $52.40. The company had a trading volume of 274,326 shares, compared to its average volume of 518,204. MoonLake Immunotherapeutics has a 52-week low of $31.42 and a 52-week high of $58.26. The stock's 50 day moving average price is $48.87 and its 200-day moving average price is $43.14. The company has a debt-to-equity ratio of 0.21, a current ratio of 16.65 and a quick ratio of 21.11. The company has a market capitalization of $3.35 billion, a P/E ratio of -18.85 and a beta of 1.27.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Deutsche Bank AG increased its position in MoonLake Immunotherapeutics by 59.8% during the fourth quarter. Deutsche Bank AG now owns 903 shares of the company's stock valued at $49,000 after acquiring an additional 338 shares during the last quarter. US Bancorp DE increased its position in MoonLake Immunotherapeutics by 114.4% during the first quarter. US Bancorp DE now owns 2,208 shares of the company's stock valued at $86,000 after acquiring an additional 1,178 shares during the last quarter. Quarry LP bought a new position in MoonLake Immunotherapeutics during the first quarter valued at $94,000. Advisors Asset Management Inc. increased its position in MoonLake Immunotherapeutics by 81.7% during the first quarter. Advisors Asset Management Inc. now owns 4,009 shares of the company's stock valued at $157,000 after acquiring an additional 1,803 shares during the last quarter. Finally, Birchview Capital LP bought a new position in MoonLake Immunotherapeutics during the fourth quarter valued at $217,000. Institutional investors own 93.85% of the company's stock.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.